HKEX: 6998
2026 Interim Report
View original source (HKEXnews)
Earlier from Edding Genor
- Edding Genor: EDG Announced Phase Ib/II Clinical Trial of GB268 Obtained IND Approval by NMPA
- Edding Genor: EDG Announced EDP167 has successfully completed the first subject dosing in its Phase II clinical trial
- Genor Biopharma: Releases Its Interim Results for 2023